CUE vs RCUS
CUE: Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate anti-tumor immunity in cancer. RCUS: A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in late-stage trials.
Side-by-side fundamentals
| Metric | CUE | RCUS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.20 | $29.97 | |
| Market cap as of 2026-07-23 | $144M | $3.7B | |
| Net margin as of 2026-07-23 | -59.6% | -156.4% | CUE higher |
| Operating margin as of 2026-07-23 | -59.9% | -168.6% | CUE higher |
| ROE as of 2026-07-23 | -98.3% | -69.0% | RCUS higher |
| ROA as of 2026-07-23 | -53.7% | -35.3% | RCUS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.19 | CUE lower |
| Revenue growth (YoY) as of 2026-07-23 | +309.6% | -15.1% | CUE higher |
| Revenue CAGR (3y) SEC XBRL | +180.5% | -4.6% | CUE higher |
| Beta as of 2026-07-23 | 2.49 | 0.81 | |
| 1-year return as of 2026-07-22 close | +26.3% | +218.4% | RCUS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.